CNS care is shifting toward one-time, disease-modifying cell and gene therapies, fueled by better delivery and approvals, while safety, cost and manufacturing remain barriers.Dublin, Sept. 15, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results